ForwardVue Pharma is an emerging biopharmaceutical company developing a small synthetic compound caroboxyamidotriazole, that acts via the novel mechanism of ORAI-1 inhibition and can be formulated to deliver potent anti-angiogenic effects for 6-12 months. Carboxyamidotriazole has been administered to over 900 patients systemically to treat advanced cancer thereby allowing more rapid progress to Phase 2 once IND enabling ocular toxicity is completed.
ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.
Company Details
- Employees
- 4
- Address
- Main Street, Cambridge,united States
- Industry
- Biotechnology
- Website
- forwardvuepharma.com
- Keywords
- Ophthalmology.
- HQ
- Cambridge
Forwardvue Pharma Questions
Forwardvue Pharma's website is forwardvuepharma.com
Forwardvue Pharma's LinkedIn profile is https://www.linkedin.com/company/forwardvue-pharma
Forwardvue Pharma has
4 employees.
View email and phone details for 4
employees at Forwardvue Pharma.
Forwardvue Pharma's industry is
Biotechnology
Forwardvue Pharma's top competitors are
Aravis Biotech Llc,
Rx Sourcing Strategies, Llc,
Revopsis Therapeutics,
Onl Therapeutics,
Kowa Pharmaceuticals America, Inc.,
Melt Pharmaceuticals,
Serina Therapeutics, Inc.,
Kalm Therapeutics,
Thiogenesis Therapeutics, Corp.,
Transaortic Medical, Inc..
Forwardvue Pharma's categories are Biotechnology
